Search…

Lates News

22/04/2026

According to AI Quick News, Southwest Securities released a research report on April 21, giving Guobang Pharmaceuticals (605507.SH) a "buy" rating. The main reasons for the rating include: 1) Review: Stable growth in revenue, short-term profits under pressure, waiting for price recovery in the animal health sector; 2) Continued high growth in the animal health business, the pharmaceutical sector is undergoing a phase of adjustment; 3) Solid platform advantages, new growth engine ready to launch. (Daily Economic News)

Latest

2 m ago

Nominee for Federal Reserve Chairman Powell responded to a question about holding press conferences after every meeting of the Federal Open Market Committee by stating that transparency is not lacking currently.

2 m ago

Nominee for Federal Reserve Chairman, Powell: It is appropriate for the Federal Reserve to hold more than four Federal Open Market Committee meetings in a year.

4 m ago

Court documents show that the New York State Attorney General accused Coinbase and Gemini of violating the state's laws prohibiting illegal gambling through their prediction markets.

5 m ago

J.P. Morgan's chief stock strategist has raised the year-end target for the S&P 500 index from the previous 7,200 points to 7,600 points, implying a potential increase of about 6.9% from Monday's closing price. The bank has also raised its annual earnings forecast for the S&P 500 index to $330 per share, up from the previous $315 per share, and has raised its 2027 earnings target from $355 per share to $385 per share.

6 m ago

Federal Reserve Chair nominee Powell: People without assets cannot benefit from a large-scale balance sheet, this statement is roughly in line with the facts.

See all latest